Atsushi Takai

8PUBLICATIONS
56CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMedical biotechnology diagnostics (incl. biosensors)Genome structure and regulation
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|May 12, 2026
Evidence-Based Clinical Practice Guidelines for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 2026.

|Mar 03, 2026
Reply to "Performance of risk models in predicting outcomes of atezolizumab and bevacizumab therapy".

Masayuki Ueno, Atsushi Takai, Hiroshi Seno

|Sep 13, 2025
Lenvatinib Versus Atezolizumab Plus Bevacizumab as First-Line Treatment for Advanced Hepatocellular Carcinoma With a CRAFITY Score of 2: A Multi-Center Retrospective Study.

Masayuki Ueno, Haruhiko Takeda, Atsushi Takai

|Jun 03, 2025
Epithelial Regnase-1 inhibits colorectal tumor growth by regulating IL-17 signaling via degradation of NFKBIZ mRNA.

Eriko Iguchi, Atsushi Takai, Natsumi Oe

|Jan 08, 2025
Efficacy and Safety of a Novel Tapered-Tip Sheath System for Biliary-Lesion Tissue Sampling: A Randomized Controlled Trial.

Hirokazu Okada, Norimitsu Uza, Tomoaki Matsumori

|Oct 21, 2024
Publisher Correction: CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study.

Masayuki Ueno, Haruhiko Takeda, Atsushi Takai

Pageof 2

Frequent Collaborators

4 joint publications

Masayuki Ueno

2 joint publications

Haruhiko Takeda

2 joint publications

Hiroshi Seno

2 joint publications

Etsuro Hatano